Pelthos Therapeutics (PTHS)
:PTHS
Want to see PTHS full AI Analyst Report?
Top Page
Pelthos Therapeutics
(PTHS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$23.00
▼(-0.09% Downside)
Action:ReiteratedDate:04/18/26
The score is held down primarily by weak financial performance (large losses and continued cash burn despite improved revenue and margins) and limited valuation support due to unprofitability. Technicals are roughly neutral. Corporate updates are a relative positive, reflecting early product uptake, portfolio expansion, and financing actions that improve near-term operating runway.
Positive Factors
Commercial traction
Early launch revenue and meaningful prescriber adoption provide durable evidence of product-market fit in a defined pediatric dermatology niche. Sustained unit growth and repeat prescribing create a scalable revenue base and support future margin expansion as fixed commercial costs are spread across higher volumes.
Negative Factors
Persistent cash burn
Material negative operating and free cash flow indicate the business remains dependent on external capital to fund operations. Continued cash burn constrains strategic optionality, forces financing events that dilute shareholders or add leverage, and creates execution risk until cash flow turns positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction
Early launch revenue and meaningful prescriber adoption provide durable evidence of product-market fit in a defined pediatric dermatology niche. Sustained unit growth and repeat prescribing create a scalable revenue base and support future margin expansion as fixed commercial costs are spread across higher volumes.
Read all positive factors
Pelthos Therapeutics (PTHS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.89M
Dividend YieldN/A
Average Volume (3M)30.94K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,355,543
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$57.14Price Target Upside148.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pelthos Therapeutics Business Overview & Revenue Model
Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children ...
How the Company Makes Money
null...
Pelthos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.52M | 0.00 | 0.00 | 0.00 | -209.05K |
| EBITDA | -30.07M | -7.17M | -6.86M | -2.32M | 0.00 |
| Net Income | -43.32M | -7.96M | -7.38M | -2.46M | -595.39K |
Balance Sheet | |||||
| Total Assets | 130.40M | 1.37M | 96.39K | 55.07K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 18.02M | 513.44K | 96.39K | 55.07K | 0.00 |
| Total Debt | 34.83M | 2.19M | 1.27M | 540.43K | 1.10M |
| Total Liabilities | 91.52M | 4.08M | 6.54M | 3.76M | 3.68M |
| Stockholders Equity | 38.88M | -2.71M | -6.44M | -3.71M | -3.68M |
Cash Flow | |||||
| Free Cash Flow | -22.69M | -5.79M | -981.03K | -1.57M | -1.59M |
| Operating Cash Flow | -22.59M | -5.79M | -981.03K | -1.57M | -1.59M |
| Investing Cash Flow | -5.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 45.34M | 6.21M | 1.02M | 1.62M | 1.59M |
Pelthos Therapeutics Risk Analysis
Pelthos Therapeutics disclosed 69 risk factors in its most recent earnings report. Pelthos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pelthos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $131.04M | -0.86 | -1197.81% | ― | ― | 27.88% | |
49 Neutral | $83.89M | -1.35 | -200.45% | ― | ― | ― | |
48 Neutral | $109.43M | -4.95 | 252.30% | ― | 370.22% | 89.54% | |
44 Neutral | $74.07M | -6.48 | 15.86% | ― | 9.69% | 98.38% | |
43 Neutral | $54.12M | -2.28 | -55.88% | ― | ― | 5.38% | |
43 Neutral | $27.65M | -2.09 | 315.97% | ― | ― | -201.53% |
* Healthcare Sector Average
PTHS
Pelthos Therapeutics
25.00
12.40
98.41%
IMUX
Immunic
9.65
-1.85
-16.09%
FBIO
Fortress Biotech
2.33
0.50
27.32%
VRCA
Verrica Pharmaceuticals
6.27
1.58
33.69%
TIL
Instil Bio
7.90
-6.58
-45.44%
TVGN
Tevogen Bio Holdings
6.66
-43.84
-86.81%
Pelthos Therapeutics Corporate Events
Business Operations and Strategy
Pelthos Highlights Infectious Disease Portfolio at Investor Meetings
Positive
Apr 14, 2026
Pelthos Therapeutics Inc., based in Durham, N.C., is a commercial-stage biopharmaceutical company focused on differentiated cutaneous infectious disease products that address unmet patient needs. Its lead product, ZELSUVMI (berdazimer) topical gel...
Business Operations and StrategyExecutive/Board Changes
Pelthos Therapeutics Appoints John M. Gay as CFO
Positive
Apr 10, 2026
On April 6, 2026, Pelthos Therapeutics’ board appointed John M. Gay as Chief Financial Officer, treasurer and secretary, with the changes becoming effective April 10, 2026, and concurrently terminated former CFO Francis Knuettel II effective...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingProduct-Related Announcements
Pelthos Highlights 2025 Results and Portfolio Expansion Progress
Positive
Mar 19, 2026
On March 19, 2026, Pelthos Therapeutics reported fourth-quarter and full-year 2025 results, highlighting the July 2025 launch of ZELSUVMI, which generated $16.2 million in net sales through year-end and drove a 28% sequential revenue increase to $...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.